Debut with psychotic symptoms of Hashimoto encephalopathy: A case report

Angela Daniela Ortiz Arce* © Henry Sánchez-Rueda©

*Corresponding author
aortizar@unsa.edu.pe

Citation
Ortiz Arce AD, Sánchez-Rueda H. Debut with psychotic symptoms of Hashimoto encephalopathy: A case report. Medwave 2022;22(9):2566

DOI
10.5867/medwave.2022.09.2566

Abstract
Hashimoto’s encephalopathy is a rare disease, first reported in 1966, with a prevalence of 2.1 in 1000 inhabitants. We present the case of a 42-year-old woman, with no relevant medical history, who suddenly started having symptoms of altered consciousness, visual hallucinations and delusions. Laboratory tests showed anti-thyroid peroxidase antibodies greater than 600 U/ml, thyroxin 0.93 U/ml, and thyroid stimulating hormone 1.60 U/ml. Magnetic resonance imaging showed bilateral subcortical focal lesions with a nonspecific demyelinating appearance. The electroencephalogram was nonspecific. The diagnosis of Hashimoto encephalopathy was made, and symptoms remitted after treatment with steroids. This article highlights the importance of conducting a comprehensive evaluation of patients with atypical psychiatric symptoms and a thorough differential diagnosis.
**INTRODUCTION**

Hashimoto’s encephalopathy is associated with Hashimoto’s disease and was first described in 1966. This disease is believed to be an immunologically mediated disorder that affects the central nervous system independently from low thyroid hormone levels [1]. Its exact pathophysiology is unknown, but most evidence points to an autoimmune vasculitis or other inflammatory processes, possibly associated with immune complex deposition and alteration of the cerebral microvasculature. Like most autoimmune diseases, it is more frequent in women with a ratio of four to one [1], and it can be concomitant with other autoimmune pathologies in up to 30% of patients [2].

Hashimoto’s encephalopathy has been seen to occur independently of Hashimoto’s disease. As it is linked to an increase in autoimmune antibodies related to thyroid pathology beyond the antithyroid peroxidase antibody, some propose a different eponym: steroid-sensitive encephalopathy associated with autoimmune thyroiditis [3].

Its clinical presentation is characterized by neuropsychiatric symptoms of varying intensity that, in some cases, may end in a coma. Neurological symptoms include stroke-like episodes, seizures, dementia, myoclonus, and myelopathies compatible with nonspecific encephalopathies [3]. Among the psychiatric symptoms, the most frequent are sensory-perceptual disturbances and behavioral and thought disturbances may also be present [4]. Finding at least one frankly elevated antithyroid antibody is a fundamental criterion. The literature indicates that the antithyroid peroxidase antibody should be greater than 200 milli-international units per milliliter (more than five times the average value). Some authors even place a cut-off point of 500 milli-international units per milliliter [5]. The first line of treatment is corticosteroids at high doses for 3 to 5 days, associated with drugs for disease complications and most patients show complete improvement after management with corticosteroids [2]. We present the clinical case of a female patient who presented with Hashimoto’s encephalopathy with a psychotic episode as a debut.

Table 1. Laboratory tests.

| Laboratory tests     | Values          |
|----------------------|-----------------|
| Hemoglobin           | 15 gr%          |
| Hematocrit           | 43.4%           |
| Platelets            | 311 x mm3       |
| Leukocytes           | 6.9 x mm3       |
| Banded neutrophils   | 0%              |
| Segmented neutrophils| 73%             |
| Eosinophils          | 0%              |
| Basophils            | 0%              |
| Lymphocytes          | 18%             |
| Monocytes            | 9%              |
| Glucose              | 99 mg/dl        |
| Creatinine           | 0.65 mg/dl      |
| Urea                 | 27 mg/dl        |
| Chlorine             | 104 mmol/L      |
| Potassium            | 3.5 mmol/L      |
| Sodium               | 140 mmol/L      |
| C-reactive protein   | 1.3 mg/L        |

gr%: grams percent. mm3: cubic millimeters. mg/dl: milligrams per deciliter. mmol/L: millimoles per deciliter. mg/L: milligrams per liter. Source: Prepared by the authors of this study.

**CASE REPORT**

For the report of this case, informed consent and institutional authorization were requested.

This is the case of a 42-year-old woman of mixed race, cohabitant, and housewife with no relevant family or medical history. Four months before her admission, she presented with constant headaches that partially resolved with outpatient analgesics. In September 2021, she had an emergency consultation at the medical service of Goyeneche Hospital with a sudden episode of confusion, psychomotor agitation, and sensory-perceptual disturbances (auditory and visual hallucinations). Clonazepam and mannitol were administered, suspecting a cerebral vascular accident. Since there was no favorable response, hospitalization was decided.

Physical examination showed normal vital signs with no other particularities. The mental examination showed a confused patient, disoriented in time and space and partially in person, with incoherent language and thoughts, the presence of nihilistic delusions (“My son is dead”, “My mother is dead”, “They
have taken all my blood”), delusions of persecution ("The police are looking for me”), bizarre delusions ("How they are going to glue the mouse skin on me? They have scraped my whole body and put blond wool on me, I am a brunette”, “My head is empty, light, flat, they have put much garbage in me, they have put glass in me”), pejorative auditory hallucinations, cenesthetic hallucinations ("I have excrement behind my head, clean it”), affective incontinence, hypoprosexia, dyscalculia, and null judgment and introspection.

In the neurological examination, anosmia was found without alteration of cranial pairs, and the rest of the neurological examination was normal. Paraclinical examinations were requested (Table 1) to rule out infection or electrolyte alteration, with results within normal parameters. A lumbar puncture was performed to rule out a neurological compromise, and resulted in normal cerebrospinal fluid (Table 2). The electroencephalogram showed no particularities, and the computed axial tomography showed a normal brain. Magnetic resonance imaging of the brain showed bilateral focal subcortical lesions with a nonspecific demyelinating aspect (Figure 1), so serological, immunological, and biochemical tests were requested. Tumor markers were negative, thyroid-stimulating hormone (TSH), thyroxine (T4), and thyroglobulins were normal. The antithyroid peroxidase antibody was elevated (600 U/ml) (Table 3). Even though the patient was clinically euthyroid, these findings supported the diagnosis of Hashimoto’s encephalopathy.

With a presumed diagnosis of Hashimoto encephalopathy, the patient started treatment with prednisone 50 milligrams per day for seven days, followed by methylprednisolone one gram per day for three days. During hospitalization, remission of neuropsychiatric symptoms was observed, so the patient was discharged with outpatient follow-ups, which she did not attend.

**DISCUSSION**

Hashimoto’s encephalopathy is a clinical entity that may present with multiple neuropsychiatric manifestations and represents a challenge for diagnosis and treatment. The age of presentation of the present case is similar to findings from a systematic review that analyzed 46 cases of Hashimoto’s encephalopathy, finding an age range of presentation at 50 years [6]. The clinical presentation, acute onset, and debut with profound atypical psychiatric manifestations (nihilistic delirium, delirium of persecution, bizarre delirium), associated with anomia, are not very frequent in the reported literature [7,8]. Chang, Jan Shun, and colleagues report three cases in which there is a predominance of visual and auditory hallucinations and, in one of them, persecution delusions associated with frank alterations of the thyroid profile and subsequent evident clinical manifestations [9]. Likewise, Amamou et al. report a case of a 39-year-old male patient who presented hypochondriac delirium and depressive

**Table 2.** Cerebrospinal fluid biochemistry.

| Cerebrospinal fluid biochemistry | Values |
|---------------------------------|--------|
| Volume                          | 2 ml   |
| Color                           | Colorless |
| Appearance                      | Transparent |
| Cell count                      | 2 x mm³ |
| Mononuclear                     | 0/μL   |
| Polymorphonuclear               | 100/μL |
| Leukocytes                      | 0-1/μL |
| Red blood cells                 | 0-1/μL |
| Normal border                   | 90/μL  |
| Crenulated border               | 10/μL  |
| Germs                           | None   |
| Glucose                         | 61 mg/dl |
| Pandy                           | Negative |
| Proteins                        | 26.7 mg/dl |
| Culture                         | Negative |

mm³: cubic millimeter. mg/dl: milligrams per deciliter. μL: microliter. ml: milliliter.

Source: Prepared by the authors of this study.

**Figure 1.** Axial view of magnetic resonance imaging of the brain, with bilateral focal subcortical lesions of nonspecific demyelinating appearance.

Source: Prepared by the authors of this study.
symptoms [8]. Churilov L et al. reported 17 cases of Hashimoto’s encephalopathy in patients with schizophrenia, in whom phobias and sleep disorders were identified in up to 52% and hallucinations in 18% of the series of cases studied [7]. Case reports with similar demographic characteristics highlight the history of previous thyroid or psychiatric pathologies associated with this entity [10,11]. Our report highlights the onset of encephalopathy with no previous medical history.

An elevated level of antithyroglobulin antibodies, in addition to cerebrospinal fluid studies, electroencephalogram, and imaging studies without significant alterations, are criteria that corroborate our clinical suspicion [7]. Finally, the recommended treatment guidelines were applied [2,10], obtaining a clinical improvement in the patient.

One of the limitations of our study is that we do not have a long-term follow-up of the presented case and lack of exclusion of other autoimmune pathologies.

We highlight the importance of comprehensively evaluating patients with atypical psychiatric symptomatology and deepen the differential diagnoses.

**CONCLUSIONS**

We recommend having special attention to sudden onset psychosis in patients without premorbid mental pathology. We also emphasize the importance of taking a detailed clinical history that will provide valuable information about the origin of psychosis since organic etiology should always be present in a differential diagnosis of psychiatric pathology and to reach a timely diagnosis and treatment.

### Table 3. Immunological tests.

| Immunological tests          | Values               |
|------------------------------|----------------------|
| Procalcitonin               | 0.04 ng/ml           |
| Lactate dehydrogenase       | 210 μL/L             |
| Complement C3               | 133 mg/dl            |
| Complement C4               | 29 mg/dl             |
| Antithyroid peroxidase antibodies | > 600 U/ml     |
| CA 125                      | 21.95 U/ml           |
| CA 15-3                     | 7.35 U/ml            |
| CA 19-9                     | 10.21 U/ml           |
| CA 72-4                     | 0.79 U/ml            |
| Carcinoembryonic antigen    | 3.55 U/ml            |
| Thyroxine                   | 0.86 U/ml            |
| Thyroid-stimulating hormone | 4.52 U/ml            |
| Vitamin B12                 | 303.6 U/ml           |
| Parathormone                | 37.9 U/ml            |

ng/ml: nanograms per milliliter. μL/L: microliter per liter. U/ml: international units per milliliter. mg/dl: milligrams per deciliter.

Source: Prepared by the authors of this study.

### Notes

**Contributor roles**

ADOA, HSR performed the conceptualization, literature analysis, writing, review, editing, final approval of the version to be published, and commitment to be responsible for all aspects of the report.

**Competing interests**

The authors declare that there are no conflicts of interest.

**Funding**

Self-financed.

**Ethics**

Informed consent was signed and institutional authorization was obtained.

**Data sharing statement**

The authors declare their willingness to provide data on request.

**Provenance and peer review**

Not commissioned. With external review by two double-blind peer reviewers.

**Language of submission**

Spanish.

### References

1. Encefalopatía de Hashimoto - UpToDate [Internet]. 2021. https://www.uptodate.com/contents/hashimoto-encephalopathy?search=encefalopatía de hashimoto&source=search_result&selectedTitle=1~11&usage_type=default&display_rank=1#H6

2. Pinedo-Torres I, Paz-Ibarra JL. Conocimientos actuales en encefalopatía de Hashimoto: revisión de la literatura. Medwave. 2018;18. https://doi.org/10.5867/medwave.2018.06.7298

3. Ferracci F, Beritati G, Moretto G. Hashimoto’s encephalopathy: Epidemiologic data and pathogenetic considerations. Journal of the Neurological Sciences. 2004;217(2):165–8. https://doi.org/10.1016/j.jns.2003.09.007

4. Boelen R, de Vries T. Clinical characteristics of paediatric Hashimoto’s encephalopathy. Eur J Paediatr Neurol. 2021;32: 122–127. https://doi.org/10.1016/j.ejpn.2021.04.006

5. Laycock K, Chaudhuri A, Fuller C, Khatami Z, Nkonge F, Stojanovic N. A novel assessment and treatment approach to patients with Hashimoto’s encephalopathy. Endocrinol Diabetes Metab Case Rep. 2018;2018. https://doi.org/10.1530/EDM-17-0117

6. Menon V, Subramanian K, Thamizh JS. Psychiatric Presentations Heraldine Hashimoto’s Encephalopathy: A Systematic Review and Analysis of Cases Reported in Literature. J Neurosci Rural Pract. 2017;8: 261–267. https://doi.org/10.4103/jnpr.jnpr_440_16

7. Churilov LP, Sobolevskaia PA, Stroeve YL. Thyroid gland and brain: Enigma of Hashimoto’s encephalopathy. Best Pract Res Clin Endocrinol Metab. 2019;33: 101364. https://doi.org/10.1016/j.beem.2019.101364
8. Amamou B, Ben Saida I, Ben Haouala A, Mhalla A, Zaatra I, Gaha L. Hashimoto’s Encephalopathy Revealed by Hypochondriacal Delusion: A Case Report Involving A Male Patient. Am J Mens Health. 2020;14: 1557988320955080. https://doi.org/10.1177/1557988320955080

9. Chang JS, Chang TC. Hashimoto’s encephalopathy: report of three cases. J Formos Med Assoc. 2014;113: 862–6. https://doi.org/10.1016/j.jfma.2011.05.012

10. Wilcox RA, To T, Koukourou A, Frasca J. Hashimoto’s encephalopathy masquerading as acute psychosis. J Clin Neurosci. 2008;15: 1301–4. https://doi.org/10.1016/j.jocn.2006.10.019

11. Arrojo M, Perez-Rodriguez MM, Mota M, Moreira R, Azevedo A, Oliveira A, et al. Psychiatric presentation of Hashimoto’s encephalopathy. Psychosom Med. 2007;69: 200–1. https://doi.org/10.1097/PSY.0b013e31803174c0
Debut con síntomas psicóticos de encefalopatía de Hashimoto: reporte de caso

Resumen
La encefalopatía de Hashimoto es una enfermedad rara reportada por primera vez en 1966 con una prevalencia de 2,1/1000 habitantes. Se presenta el caso de una mujer de 42 años, sin antecedentes médicos de importancia, quien inició un cuadro de manera súbita con alteración de conciencia, alucinaciones visuales y delusiones. En los exámenes de laboratorio se tuvo anticuerpos antiperoxidasa tiroidea mayor a 600 U/ml, tiroxina 0,93, hormona estimulante de la tiroides 1,60 U/ml, resonancia magnética con lesiones focales subcorticales bilaterales de aspecto desmielinizante inespecífico, electroencefalograma sin particularidades. Se realizó el diagnóstico de encefalopatía de Hashimoto y el cuadro remitió luego del tratamiento con corticoides. El artículo resalta la importancia de realizar una evaluación integral de los pacientes con sintomatología psiquiátrica atípica y ahondar en el diagnóstico de exclusión.

This work is licensed under a Creative Commons Attribution 4.0 International License.